Abbott Laboratories experienced upward momentum during the trading session, driven by a combination of positive strategic announcements, strong analyst support, and its attractive position as a resilient dividend aristocrat amid broader market volatility. Investors appear to be rotating back into highly stable healthcare giants that have experienced recent valuation compression. This renewed optimism has pushed the stock higher, reversing some of its recent underperformance.

A key catalyst behind the positive sentiment is Abbott’s recent global licensing agreement with ALZpath. Under this agreement, Abbott will integrate ALZpath’s proprietary pTau217 antibody into its widely used Alinity diagnostics platforms to develop a blood-based…